Abstract
The immune checkpoint inhibitors, including anti-CTLA4 and anti-PD1 agents, have revolutionised the management of some cancers, improving survival and prognosis. However, they commonly induce autoimmune endocrinopathies, including thyroid dysfunction, hypophysitis and adrenalitis. More recently, check point inhibitors targeting Programmed Cell Death Ligand 1 (PD-L1) have been introduced. We report the first case, to our knowledge, of thyroiditis associated with the PD-L1 inhibitor Atezolizumab.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
